Research indicates that treatment with the GPR68 inhibitor OGM in acute and chronic mouse colitis models reduces mucosal inflammatory responses, providing the first evidence that targeting GPR68 ameliorates mouse colitis (de Vallière et al., 2021). This evidence concerns the gene GPR68 and colitis.